Related Experiment Videos
Micropenis. II. Hypogonadotropic hypogonadism
The Johns Hopkins Medical Journal
|May 1, 1980
Summary
Hypogonadotropic hypogonadism patients with micropenis may achieve normal adult penile length with androgen therapy if prepubertal length is above -3 SD. Shorter phalluses typically remain below the normal range.
Area of Science:
- Pediatric Endocrinology
- Andrology
- Reproductive Medicine
Background:
- Hypogonadotropic hypogonadism (HH) is a condition characterized by insufficient sex hormone production.
- Micropenis is defined as penile length more than 2.5 standard deviations below the mean for age.
- Understanding factors influencing penile growth in HH is crucial for treatment strategies.
Observation:
- This study reviewed 14 male patients diagnosed with hypogonadotropic hypogonadism and micropenis.
- Nine patients were raised as males and five received androgen therapy for penile growth stimulation.
- Penile length was measured relative to standard deviations from the mean for chronological age or sexual development stage.
Findings:
- Two out of five patients receiving androgen therapy achieved normal adult penile length (between -0.2 and -2.1 SD).
- The remaining three patients on androgen therapy had significantly shorter adult penile lengths (between -3.6 and -5.2 SD).
- Prepubertal penile lengths between -2.5 and -3 SD below the mean showed potential for normal adult length with treatment.
Implications:
- Androgen therapy may be effective in normalizing penile length for some hypogonadotropic hypogonadism patients with micropenis.
- Initial penile length is a key predictor of treatment outcomes in this patient population.
- Further research is warranted to optimize androgen treatment protocols for micropenis in hypogonadotropic hypogonadism.